The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“ERBB2 and ERBB3 in human tumorigenesis ERBB2 amplification and overexpression have been reported in a number of human tumours, including in 18–25% of human breast cancers, depending on the diagnostic technique used and other factor”
MethodSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“jpg" NDATA ITEM> ]> Members of the epidermal growth factor family of transmembrane receptors (Erbb family) are potent mediators of normal cell growth and developmen”
BackgroundThe phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Self-citationTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Cited by
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationAdjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Self-citationBaselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317
Self-citationTargeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Self-citationThe ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 552
Gujrati, V., Kim, S., Kim, S.-H., Min, J. J., Choy, H. E., Kim, S. C., & Jon, S. (2014) · ACS Nano · doi:10.1021/nn405724x · Cited by 543
Serra, V, Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 528
Self-citationEvidence for archaic adaptive introgression in humans
Racimo, F., Sankararaman, S., Nielsen, R., & Huerta-Sánchez, E. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3936 · Cited by 521
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 505
Provenzano, P. P., & Keely, P. J. (2011) · Journal of Cell Science · doi:10.1242/jcs.067009 · Cited by 494
Subtype and pathway specific responses to anticancer compounds in breast cancer
Heiser, L. M., Sadanandam, A., Kuo, W.-L., Benz, S. C., Goldstein, T. C., Ng, S., Gibb, W. J., Wang, N. J., Ziyad, S., Tong, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018854108 · Cited by 475
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 471
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Li, M., Zhang, Z., Li, X., Ye, J., Wu, X., Tan, Z., Liu, C., Shen, B., Wang, X.-A., Wu, W., et al. (2014) · Nature Genetics · doi:10.1038/ng.3030 · Cited by 443
MicroRNAs and their target gene networks in breast cancer
O'Day, E., & Lal, A. (2010) · Breast Cancer Research · doi:10.1186/bcr2484 · Cited by 439
Perez, E. A., Barrios, C., Eiermann, W., Toi, M., Im, Y.-H., Conte, P., Martin, M., Pienkowski, T., Pivot, X., Burris, H. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4887 · Cited by 420
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S. T., Imai, Y., Rimm, D. L., Shirley Liu, X., & Brown, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.026 · Cited by 397
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 369
Self-citationMolecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 367
Spatial regulation of receptor tyrosine kinases in development and cancer
Casaletto, J. B., & McClatchey, A. I. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3277 · Cited by 359
Amiri-Kordestani, L., Blumenthal, G. M., Xu, Q. C., Zhang, L., Tang, S. W., Ha, L., Weinberg, W. C., Chi, B., Candau-Chacon, R., Hughes, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0012 · Cited by 351
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Oxidative stress promotes myofibroblast differentiation and tumour spreading
Toullec, A., Gerald, D., Despouy, G., Bourachot, B., Cardon, M., Lefort, S., Richardson, M., Rigaill, G., Parrini, M., Lucchesi, C., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000073 · Cited by 339
Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication
Lamichhane, T. N., Jeyaram, A., Patel, D. B., Parajuli, B., Livingston, N. K., Arumugasaamy, N., Schardt, J. S., & Jay, S. M. (2016) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-016-0457-4 · Cited by 347
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Jura, N., Shan, Y., Cao, X., Shaw, D. E., & Kuriyan, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912101106 · Cited by 338
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
“Therapy of HER2 breast cancer with anti-HER2 agents, including monoclonal antibodies and smallmolecule tyrosine kinase inhibitors, hasmarkedly improved the outcome of this disease (5).”
BackgroundSelf-citationDevelopment of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Yap, T. A., Omlin, A., & de Bono, J. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 329
Bosch, A., Eroles, P., Zaragoza, R., Viña, J. R., & Lluch, A. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.002 · Cited by 283
Targeted Therapies in Advanced Gastric Cancer
Patel, T. H., & Cecchini, M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00774-4 · Cited by 282
Phage display screening of therapeutic peptide for cancer targeting and therapy
Saw, P. E., & Song, E.-W. (2019) · Protein & Cell · doi:10.1007/s13238-019-0639-7 · Cited by 279
McDonagh, C. F., Huhalov, A., Harms, B. D., Adams, S., Paragas, V., Oyama, S., Zhang, B., Luus, L., Overland, R., Nguyen, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0820 · Cited by 278
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
Pharmacological targeting of the pseudokinase Her3
Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1658 · Cited by 205
Mendez, F. L., Watkins, J. C., & Hammer, M. F. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.06.015 · Cited by 156
Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3407 · Cited by 151
“Resistance to trastuzumab remains a challenge in the therapy of HER2-overexpressing breast cancer and efforts are being directed at identifying potential underlyingmechanisms (40).”
BackgroundSelf-citationLittlefield, P., Liu, L., Mysore, V., Shan, Y., Shaw, D. E., & Jura, N. (2014) · Science Signaling · doi:10.1126/scisignal.2005786 · Cited by 126
NSCLC and HER2: between lights and shadows
Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., Scimone, A., & Adamo, V. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000379 · Cited by 78
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73
Li, W.-Q., Hu, N., Wang, Z., Yu, K., Su, H., Wang, L., Wang, C., Chanock, S. J., Burdett, L., Ding, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068999 · Cited by 24
Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy
Ray, D., Cuneo, K. C., Rehemtulla, A., Lawrence, T. S., & Nyati, M. K. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.008 · Cited by 22
“ERBB3 is a very interesting member of this family as it has no kinase activity but can facilitate signal transduction by forming a heterodimer with another family member [15].”
Dar, G. H., Gopal, V., & Rao, M. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.01.017 · Cited by 16
Metadata
- Authors
- Baselga, J., & Swain, S. M.
- Venue
- Nature Reviews Cancer
- Published
- 2009-06-18
- Volume
- 9
- Issue
- 7
- Pages
- 463-475
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1993804787
- Cited by
- 1,142
- References
- 132
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.